LTBI Treatment Recommendations for Children by Age
For children ≥2 years old, use 3 months of weekly rifapentine plus isoniazid (3HP) as the preferred regimen, while for children <2 years old, use 4 months of daily rifampin (4R), as rifapentine is not approved for this younger age group 1.
Age-Based Treatment Algorithm
Children ≥2 Years Old
The 3-month weekly rifapentine plus isoniazid (3HP) regimen is the preferred first-line treatment with strong recommendation and moderate-quality evidence 1. This regimen offers:
- Superior completion rates compared to longer regimens (83.5% vs 68.8% for 9-month isoniazid) 2
- Equivalent efficacy in preventing TB disease progression 3, 4
- Once-weekly dosing that significantly improves adherence
- Shorter duration reducing loss to follow-up and relocation-related non-completion 2
Alternative preferred regimens for children ≥2 years include 1:
- 4 months of daily rifampin (4R) - strong recommendation, moderate evidence
- 3 months of daily isoniazid plus rifampin (3HR) - conditional recommendation
Children <2 Years Old
Use 4 months of daily rifampin (4R) as the treatment of choice 1. Rifapentine-based regimens are not approved for children under 2 years of age due to lack of safety and efficacy data in this population.
Alternative for children <2 years:
- 6 months of daily isoniazid (6H) - strong recommendation for HIV-negative children of all ages 1
Key Evidence Supporting These Recommendations
The 2020 CDC/NTCA guidelines establish rifamycin-based shorter regimens as preferred over traditional isoniazid monotherapy across all pediatric age groups where approved 1. Network meta-analysis demonstrates that isoniazid plus rifapentine combinations rank highest for preventing TB disease incidence (10% probability in SUCRA) and death (20%) 4.
Recent systematic review data (2026) confirms that shorter rifamycin-containing regimens result in little to no difference in TB disease development compared to 9-month isoniazid (OR 0.19,95% CI 0.03-1.12, moderate-certainty evidence), while treatment completion is significantly higher (OR 0.51,95% CI 0.42-0.62) 3.
Among children <15 years specifically, 2-3 month courses of daily isoniazid plus rifampin show equivalent effectiveness to 6-month or longer isoniazid courses, with no differences in TB disease progression, adverse effects, or hepatotoxicity 1.
Critical Safety Considerations
Hepatotoxicity risk is lower with shorter rifamycin-based regimens compared to prolonged isoniazid monotherapy 1, 3. However, hepatotoxicity may be greater when isoniazid and rifampin are combined versus either drug alone 1.
Drug interactions are the primary concern with rifamycin-based regimens, particularly affecting:
- Antiretroviral therapy in HIV-positive children
- Oral contraceptives in adolescents
- Azole antifungals
- Warfarin
Rifapentine has fewer drug interactions than rifampin, making 3HP preferable when drug-drug interactions are a concern 1.
Common Pitfalls to Avoid
Do not use 9-month isoniazid as first-line treatment - completion rates are significantly lower (46.9% vs 30.3% for 3HR), making it less effective despite equivalent efficacy 5
Do not prescribe rifapentine for children <2 years - safety data are insufficient in this age group
Ensure adequate TB disease exclusion before starting treatment - acquired drug resistance can occur if active TB is missed, particularly with rifampin-containing regimens 1
Monitor for hepatotoxicity more closely with combination regimens - though overall rates are low (1.5% for 4R, 0.7% for 9H), combined isoniazid-rifampin therapy may increase risk 1, 2
Consider management setting - primary care settings, non-metropolitan locations, and non-pediatric specialists show higher treatment incompletion rates, requiring enhanced monitoring 5